TTOO Capex To Operating Cash Flow vs Free Cash Flow Yield Analysis
TTOO Stock | USD 0.39 0.06 14.33% |
T2 Biosystms financial indicator trend analysis is much more than just breaking down T2 Biosystms prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether T2 Biosystms is a good investment. Please check the relationship between T2 Biosystms Capex To Operating Cash Flow and its Free Cash Flow Yield accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in T2 Biosystms. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.
Capex To Operating Cash Flow vs Free Cash Flow Yield
Capex To Operating Cash Flow vs Free Cash Flow Yield Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of T2 Biosystms Capex To Operating Cash Flow account and Free Cash Flow Yield. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between T2 Biosystms' Capex To Operating Cash Flow and Free Cash Flow Yield is -0.33. Overlapping area represents the amount of variation of Capex To Operating Cash Flow that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of T2 Biosystms, assuming nothing else is changed. The correlation between historical values of T2 Biosystms' Capex To Operating Cash Flow and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Operating Cash Flow of T2 Biosystms are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Capex To Operating Cash Flow i.e., T2 Biosystms' Capex To Operating Cash Flow and Free Cash Flow Yield go up and down completely randomly.
Correlation Coefficient | -0.33 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Capex To Operating Cash Flow
Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Most indicators from T2 Biosystms' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into T2 Biosystms current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in T2 Biosystms. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.As of the 13th of December 2024, Enterprise Value is likely to grow to about 75.5 M, while Selling General Administrative is likely to drop about 26 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 6.6M | 6.1M | 5.3M | 4.9M | Depreciation And Amortization | 2.5M | 2.3M | 859K | 1.1M |
T2 Biosystms fundamental ratios Correlations
Click cells to compare fundamentals
T2 Biosystms Account Relationship Matchups
High Positive Relationship
High Negative Relationship
T2 Biosystms fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 28.5M | 79.1M | 60.5M | 34.4M | 34.8M | 43.7M | |
Short Long Term Debt Total | 44.8M | 55.8M | 57.1M | 59.2M | 49.5M | 42.0M | |
Other Current Liab | 13.6M | 6.4M | 7.2M | 6.0M | 9.9M | 6.8M | |
Total Current Liabilities | 60.6M | 9.8M | 11.7M | 10.5M | 56.2M | 59.0M | |
Total Stockholder Equity | (34.0M) | 8.7M | (12.9M) | (40.0M) | (28.0M) | (26.6M) | |
Other Liab | 46K | 4.8M | 4.6M | 4.9M | 5.6M | 5.9M | |
Property Plant And Equipment Net | 9.2M | 14.8M | 14.4M | 13.3M | 9.1M | 9.8M | |
Net Debt | 33.7M | 39.0M | 34.9M | 48.9M | 33.8M | 35.5M | |
Retained Earnings | (376.2M) | (423.0M) | (472.2M) | (534.5M) | (584.3M) | (555.1M) | |
Accounts Payable | 3.8M | 2.1M | 2.8M | 1.3M | 1.5M | 1.6M | |
Cash | 11.0M | 16.8M | 22.2M | 10.3M | 15.7M | 28.6M | |
Non Current Assets Total | 9.6M | 25.5M | 16.1M | 15.0M | 9.6M | 11.6M | |
Cash And Short Term Investments | 11.0M | 42.2M | 32.2M | 10.3M | 15.7M | 31.0M | |
Common Stock Total Equity | 36K | 44K | 51K | 147K | 169.1K | 177.5K | |
Common Stock Shares Outstanding | 9.1K | 24.3K | 31.8K | 51.0K | 2.6M | 2.7M | |
Liabilities And Stockholders Equity | 28.5M | 79.1M | 60.5M | 34.4M | 34.8M | 43.7M | |
Non Current Liabilities Total | 1.9M | 60.6M | 61.8M | 63.9M | 6.7M | 6.3M | |
Other Current Assets | 1.4M | 2.7M | 3.1M | 2.6M | 3.3M | 1.7M | |
Other Stockholder Equity | 342.1M | 431.5M | 459.2M | 494.6M | 556.3M | 315.0M | |
Total Liab | 62.5M | 70.4M | 73.4M | 74.4M | 62.8M | 50.8M | |
Property Plant And Equipment Gross | 9.2M | 14.8M | 14.4M | 13.3M | 23.9M | 25.1M | |
Total Current Assets | 18.9M | 53.6M | 44.4M | 19.4M | 25.2M | 35.3M | |
Short Term Debt | 42.9M | 1.2M | 1.2M | 2.7M | 44.5M | 46.7M | |
Common Stock | 49K | 147K | 166K | 8K | 4K | 3.8K | |
Property Plant Equipment | 5.8M | 14.8M | 14.4M | 13.3M | 15.3M | 9.5M | |
Net Tangible Assets | (32.1M) | 8.7M | (12.9M) | (40.0M) | (36.0M) | (34.2M) | |
Current Deferred Revenue | 285K | 230K | 518K | 172K | 224K | 212.8K | |
Net Receivables | 2.8M | 5.1M | 5.1M | 2.2M | 1.4M | 2.2M | |
Retained Earnings Total Equity | (266.1M) | (317.2M) | (376.2M) | (423.0M) | (380.7M) | (399.7M) | |
Capital Surpluse | 267.4M | 328.5M | 342.1M | 431.5M | 496.3M | 308.8M | |
Inventory | 3.6M | 3.6M | 3.9M | 4.3M | 4.8M | 2.9M | |
Short Long Term Debt | 40.7M | 42.4M | 42.9M | 41.3M | 47.5M | 27.2M | |
Capital Lease Obligations | 3.9M | 10.5M | 9.4M | 9.6M | 8.2M | 6.1M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in T2 Biosystms. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of T2 Biosystms. If investors know TTOO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about T2 Biosystms listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.03) | Revenue Per Share 0.999 | Quarterly Revenue Growth (0.01) | Return On Assets (0.90) | Return On Equity (6.22) |
The market value of T2 Biosystms is measured differently than its book value, which is the value of TTOO that is recorded on the company's balance sheet. Investors also form their own opinion of T2 Biosystms' value that differs from its market value or its book value, called intrinsic value, which is T2 Biosystms' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because T2 Biosystms' market value can be influenced by many factors that don't directly affect T2 Biosystms' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between T2 Biosystms' value and its price as these two are different measures arrived at by different means. Investors typically determine if T2 Biosystms is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, T2 Biosystms' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.